CollPlant Biotechnologies
CLGN
18 hedge funds and large institutions have $13.1M invested in CollPlant Biotechnologies in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
22% more capital invested
Capital invested by funds: $10.7M → $13.1M (+$2.37M)
0.01% more ownership
Funds ownership: 1.43% → 1.43% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 21 → 18 (-3)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMOV
Investment Management of Virginia
Richmond,
Virginia
|
+$413K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$41.7K |
| 3 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$6.5K |
| 4 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$2.74K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$191K |
| 2 |
Jane Street
New York
|
-$90K |
| 3 |
FIA
FNY Investment Advisers
New York
|
-$35K |
| 4 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
-$29.8K |
| 5 |
PA
Parallel Advisors
San Francisco,
California
|
-$25.6K |
CLGN Hedge Fund Activity: Q4 2022 in Review
18 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q4 2022, worth a combined $13.1M — up 22% from $10.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CLGN and 2 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Investment Management of Virginia, adding an estimated $413K. The largest seller was LPL Financial, exiting entirely with an estimated $191K sold.
- 18 institutional investors held CollPlant Biotechnologies (CLGN) as of Q4 2022, down from 21 in Q3 2022.
- Funds reported $13.1M of CollPlant Biotechnologies stock for Q4 2022, up 22% quarter-over-quarter.
- 2 funds opened new CollPlant Biotechnologies positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest CollPlant Biotechnologies buyer in Q4 2022 was Investment Management of Virginia, an estimated $413K added.
- The largest CollPlant Biotechnologies seller in Q4 2022 was LPL Financial, an estimated $191K sold.
Based on aggregated 13F filings for Q4 2022.